Eris Lifesciences Limited

Eris Lifesciences Limited (ERIS) is a small-cap Healthcare company valued at ₹15,832 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Eris Lifesciences Limited last traded at ₹1,141.9, modestly down 0.60% on the day.

Recent developments

On 2026-06-30, the company reported its latest quarter results, showing revenue of ₹873 crore and net profit of ₹143 crore, up 13.0% and 14.7% respectively from the same quarter a year earlier. On 2026-05-29, the company announced a dividend of ₹7.21 per share, with the ex-date set for that day.

Financial performance

The company's business is improving, with annual revenue rising 8.1% and annual net profit surging 72.7%. The latest quarter saw revenue grow 13.0% compared to the same quarter a year earlier, while net profit increased 14.7%. The net profit margin expanded 7.7 percentage points to 20.7%, and return on equity remained at 15.9%.

Valuation multiples

The stock trades at 25.2 times earnings, a discount to the Healthcare median of 32.0, 4.81 times book value. It yields 0.5%.

Things to watch

The stock is 31.6% below its 52-week high, and promoter shares pledged account for 16.85% of promoter holding. The foreign institutional holding decreased by 0.64 percentage points in the quarter, while the domestic institutional holding increased by 0.37 percentage points.

Where it stands

The company has shown strong growth in both revenue and net profit over the past year and quarter, with a significant expansion in the net profit margin. The stock is currently trading 31.6% below its 52-week high, and promoter shares pledged represent a notable portion of their holding.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.